Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Noxopharm Ltd. ( (AU:NOX) ) just unveiled an announcement.
Noxopharm has successfully completed the clinical component of its HERACLES trial, reporting that the second and final multiple-dose cohort of its topical drug candidate SOF-SKN was safe and well tolerated across all dosing groups. The positive safety profile, combined with strong participant compliance and rapid trial progression, clears the way for Phase II-enabling studies and drug scale-up, advancing SOF-SKN’s development for cutaneous lupus erythematosus and potentially other autoimmune-related skin diseases. The outcome strengthens Noxopharm’s position in the competitive autoimmune market and supports broader commercial prospects for its Sofra platform, which targets a range of immune-related conditions with significant global market potential.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotechnology company focused on developing novel treatments for cancer and inflammatory and autoimmune diseases, including technologies aimed at improving the safety profile of mRNA medicines. Its R&D pipeline is built around two proprietary platforms: Sofra, which targets inflammation, autoimmunity, mRNA drug enhancement and oncology, and Chroma, which is focused on oncology applications within large and growing global markets for autoimmune disease therapeutics and immuno-oncology.
Average Trading Volume: 74,483
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$22.21M
See more insights into NOX stock on TipRanks’ Stock Analysis page.